BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.6%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$10.2B
AUM Growth
+$10.2B
(+8.4%)
Cap. Flow
+$197M
Cap. Flow
% of AUM
1.92%
Top 10 Holdings %
Top 10 Hldgs %
30.33%
Holding
228
New
12
Increased
78
Reduced
41
Closed
15
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$72M |
| 2 |
Tandem Diabetes Care
TNDM
|
$48M |
| 3 |
IQVIA
IQV
|
$42.6M |
| 4 |
Adaptive Biotechnologies
ADPT
|
$39.3M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$39M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$238M |
| 2 |
Moderna
MRNA
|
$62.9M |
| 3 |
Cigna
CI
|
$45.4M |
| 4 |
Bristol-Myers Squibb
BMY
|
$41.5M |
| 5 |
DaVita
DVA
|
$39.6M |
Sector Composition
| 1 | Healthcare | 96.41% |
| 2 | Industrials | 0.94% |
| 3 | Technology | 0.31% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Moderna
MRNA
$9.37B
| $597M | 5.83% | 2,542,300 -267,650 | -10% | -$62.9M |
|
2
Ionis Pharmaceuticals
IONS
$6.79B
| $396M | 3.87% | 9,930,245 +946,011 | +11% | +$37.7M |
|
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $350M | 3.41% | 1,733,694 +356,990 | +26% | +$72M |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $294M | 2.87% | 3,017,751 -256,800 | -8% | -$25M |
|
5
argenx
ARGX
$43.6B
| $293M | 2.86% | 974,038 +19,484 | +2% | +$5.87M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $263M | 2.56% | 1,549,092 -78,022 | -5% | -$13.2M |
|
7
Incyte
INCY
$16.5B
| $250M | 2.44% | 2,971,400 -34,300 | -1% | -$2.89M |
|
8
Agios Pharmaceuticals
AGIO
$2.19B
| $240M | 2.34% | 4,352,992 -184,100 | -4% | -$10.1M |
|
9
Fate Therapeutics
FATE
$120M
| $227M | 2.21% | 2,613,536 +404,200 | +18% | +$35.1M |
|
10
MacroGenics
MGNX
$112M
| $198M | 1.93% | 7,376,026 +1,348,100 | +22% | +$36.2M |
|
11
Intuitive Surgical
ISRG
$170B
| $186M | 1.81% | 202,095 -18,680 | -8% | -$17.2M |
|
12
Biogen
BIIB
$19.4B
| $183M | 1.79% | 528,100 -30,300 | -5% | -$10.5M |
|
13
Elevance Health
ELV
$71.8B
| $178M | 1.74% | 465,976 +80,428 | +21% | +$30.7M |
|
14
Arvinas
ARVN
$568M
| $172M | 1.68% | 2,237,403 +165,900 | +8% | +$12.8M |
|
15
Abbott
ABT
$231B
| $160M | 1.56% | 1,377,499 -15,500 | -1% | -$1.8M |
|
16
CRISPR Therapeutics
CRSP
$4.71B
| $157M | 1.53% | 966,884 -11,500 | -1% | -$1.86M |
|
|
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $147M | 1.44% | 3,609,919 -50,000 | -1% | -$2.04M |
|
|
RDUS
18
DELISTED
Radius Health, Inc.
RDUS
| $137M | 1.34% | 7,531,414 | – | – |
|
19
UnitedHealth
UNH
$281B
| $137M | 1.34% | 343,051 -14,330 | -4% | -$5.74M |
|
|
SAGE
20
DELISTED
Sage Therapeutics
SAGE
| $134M | 1.31% | 2,364,204 +553,500 | +31% | +$31.4M |
|
21
Danaher
DHR
$147B
| $130M | 1.27% | 482,940 +9,800 | +2% | +$2.63M |
|
22
Humana
HUM
$36.5B
| $125M | 1.22% | 282,755 -5,964 | -2% | -$2.64M |
|
|
MYOV
23
DELISTED
Myovant Sciences Ltd.
MYOV
| $120M | 1.17% | 5,269,039 +75,000 | +1% | +$1.71M |
|
24
Becton Dickinson
BDX
$55.3B
| $112M | 1.09% | 460,965 | – | – |
|
|
AXNX
25
DELISTED
Axonics, Inc. Common Stock
AXNX
| $110M | 1.07% | 1,730,471 +274,197 | +19% | +$17.4M |
|